Expanded Access Policy for HMI-115

HopeMed (Hope Medicine) is a science-driven, clinical-stage biopharmaceutical company.HMI-115 (BAY 1158061) is a specific human antibody that blocks the prolactin receptor. We plan to conduct phase 3 studies to evaluate the efficacy and safety of HMI-115 in women with moderate to severe pain associated with endometriosis.

HopeMed do not have an extended Access Policy for HMI-115. We recommend that interested patients participate in the treatment of this product through clinical trials. They can discuss the detailed content of the trial with doctors or visit the following website to learn about the trial information: https://www.hopemedinc.com/en Or visit https://clinicaltrials.gov Search by company, disease or medication.

If you have additional questions, please speak with your physician or contact HopeMed at Juncheng.Jiang@hopemedinc.com.

Consistent with the 21st Century Cures Act, HopeMed may revise this policy at any time.